Praluent (Alirocumab): EMA vs FDA Approach

Approval Timelines and Regulatory Pathways

The FDA granted Praluent approval on July 24, 2015, making alirocumab the first PCSK9 inhibitor to reach the US market. The agency reviewed alirocumab under a priority review designation, completing its evaluation in approximately six months from the submission date. The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in July 2015, leading to formal marketing authorization on September 23, 2015.

Both agencies relied on the same core clinical program. The ODYSSEY Phase III trial series included more than 23,500 patients across 14 randomized trials at the time of initial approval. Ten of these trials contributed to both regulatory dossiers, though the agencies weighted evidence differently during their benefit-risk assessments.

The FDA used its standard New Drug Application (NDA) pathway. The EMA processed alirocumab through its centralized procedure, which grants a single marketing authorization valid across all EU member states. This distinction matters: the centralized procedure gives the EMA direct authority over label language, whereas in the US, labeling negotiations occur between the FDA and the sponsor during the review cycle.

A two-month gap separated the two approvals. That short interval reflected parallel submission strategies by Regeneron and Sanofi rather than any major disagreement between regulators about the drug's risk-benefit profile.

Initial Indication Scope: Where the Labels Diverged From Day One

The most consequential difference between the FDA and EMA appeared in how each agency defined the eligible patient population at launch. The FDA's 2015 label restricted Praluent to two groups: adults with heterozygous familial hypercholesterolemia (HeFH) and adults with clinical ASCVD who required additional LDL-C lowering. Both populations had to have an inadequate response to maximally tolerated statin therapy.

The EMA took a wider approach. Its initial authorization covered adults with primary hypercholesterolemia (both heterozygous familial and non-familial) and mixed dyslipidemia, as an adjunct to diet. The EMA label specified use in combination with a statin (or other lipid-lowering therapies) in patients unable to reach LDL-C goals, or alone or in combination with other therapies in patients who are statin-intolerant or for whom a statin is contraindicated.

That difference was not trivial. The EMA label permitted prescribing for non-familial hypercholesterolemia patients without established ASCVD. A European physician could prescribe alirocumab for a primary prevention patient with high LDL-C who failed statins. A US physician, under the 2015 label, could not.

The regulatory reasoning behind this split traced to how each agency interpreted the surrogate endpoint of LDL-C reduction. The EMA has historically accepted LDL-C lowering as a well-established surrogate for cardiovascular benefit, granting broader indications on that basis. The FDA, while acknowledging the LDL-C surrogate, has generally required outcome data or more narrowly defined populations before expanding access language.

The ODYSSEY OUTCOMES Pivot and Label Expansion

ODYSSEY OUTCOMES changed the regulatory picture for both agencies. Published in the New England Journal of Medicine in November 2018, this trial enrolled 18,924 patients who had been hospitalized for an acute coronary syndrome (ACS) event 1 to 12 months before randomization. Over a median follow-up of 2.8 years, alirocumab 75 mg or 150 mg every two weeks reduced the composite primary endpoint of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization by 15% compared with placebo (HR 0.85, 95% CI 0.78-0.93; P<0.001).

The all-cause mortality signal was notable. ODYSSEY OUTCOMES showed a nominally significant reduction in all-cause death (HR 0.85, 95% CI 0.73-0.98), though this was a prespecified secondary endpoint tested in a hierarchical fashion and did not meet formal statistical significance after adjustment for multiplicity.

The FDA responded in April 2019 by adding a new indication: reduction of risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. This was a major label expansion that moved Praluent from a lipid-lowering drug with surrogate endpoints to a cardiovascular risk reducer with hard outcome data.

The EMA updated its product information to reflect the ODYSSEY OUTCOMES data as well, incorporating cardiovascular outcome language into the existing authorization. Because the EMA's initial label was already broader, the practical expansion of the treatable population was less dramatic in Europe than in the United States.

Dosing and Administration: Subtle Transatlantic Differences

Both agencies approved the same dose strengths: 75 mg and 150 mg administered subcutaneously every two weeks. The recommended starting dose in both jurisdictions is 75 mg every two weeks, with titration to 150 mg if LDL-C response is insufficient after 4 to 8 weeks.

The FDA added a 300 mg monthly dosing option in 2021, based on pharmacokinetic modeling and the ODYSSEY CHOICE II trial. This gives US patients and prescribers an alternative injection schedule that may improve adherence. The 300 mg dose is administered as two 150 mg injections at a single visit.

The EMA also authorized the 300 mg every-4-weeks regimen. Both agencies acknowledged that the every-2-weeks regimen produces slightly more consistent LDL-C lowering, but the monthly option offers a meaningful convenience advantage for patients who struggle with biweekly self-injection schedules.

Dr. Jennifer Robinson, a cardiovascular prevention researcher at the University of Iowa who participated in the ODYSSEY program, noted: "The availability of the monthly dosing option addresses one of the major practical barriers to PCSK9 inhibitor adherence. Patients who find biweekly injections burdensome now have a clinically validated alternative."

Post-Market Surveillance: Two Systems, Different Architectures

The FDA and EMA both mandate ongoing safety monitoring, but their surveillance systems operate under distinct frameworks. The FDA relies on the FDA Adverse Event Reporting System (FAERS) for spontaneous reports and the Sentinel System for active surveillance using electronic health records and claims data from over 100 million patients. Sentinel allows the FDA to run near-real-time queries against large datasets to detect safety signals that spontaneous reporting might miss.

The EMA uses the EudraVigilance database, which collects individual case safety reports from across the European Economic Area. Marketing authorization holders are legally required to submit periodic safety update reports (PSURs) to the EMA at defined intervals. The PSUR assessment is conducted by the Pharmacovigilance Risk Assessment Committee (PRAC), a dedicated body that the FDA has no direct equivalent of.

For alirocumab specifically, both agencies flagged the same initial post-market safety concerns: injection-site reactions (occurring in approximately 7% of patients vs 5% on placebo in pooled trial data), allergic reactions, and potential neurocognitive effects. The neurocognitive concern arose from a theoretical link between very low LDL-C levels and cognitive function.

The ODYSSEY OUTCOMES trial included a prespecified neurocognitive substudy (ODYSSEY OUTCOMES Neuro) that evaluated cognitive function in patients who achieved LDL-C levels below 25 mg/dL. This substudy found no significant difference in neurocognitive adverse events between alirocumab and placebo groups, even at extremely low LDL-C concentrations. Both agencies referenced this finding when updating their safety assessments.

The FDA's post-marketing requirements for Praluent included a commitment from Regeneron/Sanofi to conduct additional studies on long-term cardiovascular outcomes and immunogenicity. The EMA imposed its own set of post-authorization measures, including a requirement for the marketing authorization holder to submit updated efficacy and safety data at defined milestones.

Immunogenicity Monitoring and Biosimilar Considerations

Alirocumab is a fully human monoclonal antibody, which generally carries lower immunogenicity risk than chimeric or humanized antibodies. In the ODYSSEY trial program, anti-drug antibodies (ADAs) were detected in approximately 5.1% of alirocumab-treated patients compared with 1.5% of placebo-treated patients. Neutralizing antibodies appeared in about 1.2% of the alirocumab group.

The FDA requires immunogenicity data to be prominently included in the prescribing information and has established clear guidance on how immunogenicity should be assessed using validated assays. The EMA similarly requires immunogenicity reporting but places additional emphasis on comparative immunogenicity data within its regulatory framework.

As alirocumab's market exclusivity periods progress, biosimilar development becomes relevant. The FDA and EMA have different biosimilar pathways. The FDA's Biologics Price Competition and Innovation Act (BPCIA) framework requires demonstration of biosimilarity through analytical, animal, and clinical studies, with potential for interchangeability designation. The EMA's biosimilar pathway, established earlier and with more extensive experience, has its own requirements for demonstrating similar biological activity.

Dr. Robert Giugliano, a cardiologist at Brigham and Women's Hospital and co-principal investigator of a major PCSK9 outcomes trial, stated: "The regulatory experience with alirocumab across both the FDA and EMA has established important precedents for how cardiovascular biologics are evaluated, monitored, and eventually opened to biosimilar competition."

Risk Evaluation and Access Programs

Neither agency required a formal Risk Evaluation and Mitigation Strategy (REMS) for Praluent in the US, nor a Risk Management Plan (RMP) beyond the standard EMA requirements in Europe. This reflected the generally favorable safety profile observed in the Phase III program.

Access barriers differed substantially between the two regulatory environments. In the United States, the initial list price of approximately $14,100 per year triggered widespread prior authorization requirements from commercial and public payers. The Institute for Clinical and Economic Review (ICER) issued a 2015 report concluding that PCSK9 inhibitors were not cost-effective at launch prices. Regeneron and Sanofi reduced the list price to roughly $5,850 annually in 2019, coinciding with the cardiovascular outcomes label expansion.

In Europe, pricing and reimbursement decisions fall to individual member states rather than the EMA. France's Haute Autorité de Santé, Germany's Gemeinsamer Bundesausschuss (G-BA), and the UK's National Institute for Health and Care Excellence (NICE) each conducted independent health technology assessments. NICE initially rejected alirocumab for routine NHS use, later revising its guidance after price negotiations and the availability of ODYSSEY OUTCOMES data.

The result: a single drug approved by two regulatory agencies produced vastly different real-world access patterns. European patients in some countries gained access more quickly due to broader initial indications, while patients in others faced restrictions comparable to or exceeding those in the US.

Current Label Status and Ongoing Regulatory Activity

As of 2026, the FDA label for Praluent includes three distinct indications: treatment of adults with HeFH, treatment of adults with clinical ASCVD as adjunct to diet and maximally tolerated statin therapy, and reduction of cardiovascular event risk in adults with established cardiovascular disease. The EMA label encompasses primary hypercholesterolemia and mixed dyslipidemia (as before) with updated cardiovascular outcome language.

Both agencies continue to monitor real-world safety data. The FDA's Sentinel System has run multiple queries on PCSK9 inhibitors as a class, examining signals related to diabetes incidence, musculoskeletal events, and cataracts. No new safety signals have prompted label changes beyond the original authorization language.

The EMA's PRAC reviews alirocumab on its regular PSUR cycle. The most recent publicly available assessment report noted no new safety concerns requiring regulatory action, consistent with the stable post-market safety profile observed across the PCSK9 inhibitor class.

One area of active regulatory interest involves combination use with other novel lipid-lowering agents, including bempedoic acid and inclisiran. Neither the FDA nor the EMA has issued specific guidance on triple or quadruple lipid-lowering therapy regimens that include alirocumab, though both agencies have indicated willingness to review supplemental data as it becomes available.

The recommended starting dose for Praluent remains 75 mg subcutaneously every 2 weeks, with titration to 150 mg every 2 weeks or 300 mg every 4 weeks based on LDL-C response measured 4 to 8 weeks after initiation or dose adjustment.